Serum HBV RNA is detectable during nucleoside/nucleotide analogue therapy as a result of unaffected RNA replicative intermediates or interrupted reverse transcription. We studied the predictive value of serum HBV RNA for initial virological response during nucleoside analogue therapy.
Methods
Serum HBV RNA was quantified before and at 12 and 24 weeks of lamivudine or entecavir therapy. Serum HBV DNA was measured every 4–12 weeks during treatment to define initial virological response.
Results
Serum HBV RNA was detectable in 21 of 52 (40%) consecutive patients with a mean of 5.2 log copies/ml (male/female 35/17, mean age of 60 years with a range of 31–82, 44% HBeAg-positive, and 26 with lamivudine and 26 with entecavir) before treatment. Serum HBV RNA level at week 12 in patients with an interval from detectable to undetectable serum HBV DNA level <16 weeks was significantly lower than those with an interval ≥16 weeks (3.8 +3.8 versus 6.6 +3.5 log copies/ ml, P=0.013). After adjustment for serum HBV DNA level at week 12, serum quantatitive HBsAg level at week 12 and pretreatment ALT level, low serum HBV RNA level at week 12 predicted a shorter interval to undetectable serum HBV DNA level (adjusted hazard ratio =0.908, 95% CI 0.829, 0.993, P=0.035).
Conclusions
Low serum HBV RNA level at week 12 of nucleoside analogue therapy independently predicts initial virological response in treated chronic hepatitis B patients. Serum HBV RNA levels may thus be useful for optimizing treatment of chronic hepatitis B.
References
1.
LeeW.M.Hepatitis B virus infection.N Engl J Med1997; 337: 1733–1745.
2.
KaoJ.H., ChenD.S.Overview of hepatitis B and C viruses. In GoedertJ.J. (Editor). Infectious causes of cancer: targets for intervention. Totowa: Humana Press2000; pp. 313–330.
3.
McQuillanG.M., TownsendT.R., FieldsH.A., CarrolM., LeahyM., PolkB.F.Seroepidemiology of hepatitis B virus infection in the United States.Am J Med1989; 87Suppl 3A: 5S–10S.
4.
ChenD.S.From hepatitis to hepatoma: lessons from type B viral hepatitis.Science1993; 262: 369–370.
5.
ChenD.S.Fighting against viral hepatitis: lessons from Taiwan.Hepatology2011; 54: 381–392.
6.
DoongS.L., TsaiC.H., SchinaziR.F., LiottaD.C., ChengY.C.Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues.Proc Natl Acad Sci U S A1991; 88: 8495–8499.
7.
ZhangW., HackerH.J., TokusM., BockT., SchroderC.H.Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy.J Med Virol2003; 71: 24–30.
8.
HatakeyamaT., NoguchiC., HiragaN.Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.Hepatology2007; 45: 1179–1186.
9.
HuangY.W., ChayamaK., TsugeM.Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B.Antivir Ther2010; 15: 177–184.
10.
TsugeM., MurakamiE., ImamuraM.Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients.J Gastroenterol2013; 48: 1188–1204.
11.
LiawY.F.Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.Antivir Ther2006; 11: 669–679.
European Association For The Study Of The Liver.EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
14.
LiawY.F., KaoJ.H., PiratvisuthT.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.Hepatol Int2012; 6: 531–561.
15.
JanssenH.L., SonneveldM.J., BrunettoM.R.Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?Gut2012; 61: 641–645.
16.
KeeffeE.B., ZeuzemS., KoffR.S.Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol2007; 5: 890–897.
LocarniniS., HatzakisA., HeathcoteJ.Management of antiviral resistance in patients with chronic hepatitis B.Antivir Ther2004; 9: 679–693.
19.
LaiC.L., ShouvalD., LokA.S.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med2006; 354: 1011–1020.
20.
YaoG., ChenC., LuW.Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China.Hepatol Int2007; 1: 365–372.
21.
RokuharaA., MatsumotoA., TanakaE.Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy.J Gastroenterol2006; 41: 785–790.
